Publicaciones en colaboración con investigadores/as de Institut d'Investigació Biomédica de Bellvitge (6)

2024

  1. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells

    Gut, Vol. 73, Núm. 9, pp. 1489-1508

2018

  1. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial

    Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444

  2. Increased plasma levels of galectin-1 in pancreatic cancer: Potential use as biomarker

    Oncotarget, Vol. 9, Núm. 68, pp. 32984-32996

2017

  1. Optimization of RAS/BRAF mutational analysis confirms improvement in patient selection for clinical benefit to anti-EGFR treatment in metastatic colorectal cancer

    Molecular Cancer Therapeutics, Vol. 16, Núm. 9, pp. 1999-2007

2015

  1. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633